All In Biotech

Drug Trial Radar · NCT04375800

Doravirine (DOR) in Human Immunodeficiency Virus (HIV)-Infected Children Aged 4 Weeks to <12 Years and <45 kg (MK-1439-066)

A Phase 2 Clinical Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of Doravirine and Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate in Participants With HIV-1, Who Are 4 Weeks to Less Than 12 Years of Age and Weigh Less Than 45 kg

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

84

Planned (sponsor's estimate)

Start

Feb 3, 2021

Primary completion

Nov 12, 2028

Study completion Apr 11, 2034

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
May 5, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 4 weeks, up to 11 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single-group, open-label, multi-site study in pediatric participants with human immunodeficiency virus type 1 (HIV-1) infection, aged 4 weeks to \<12 years and weighing \<45 kg, who are treatment-naive (TN) or have been virologically suppressed (VS) on stable combination antiretroviral therapy (cART) for ≥3 months with no history of treatment failure. The primary objectives are: * To evaluate the steady state pharmacokinetics (PK) of doravirine (DOR) \[MK-1439\] when given in combination with 2 nucleoside/nucleotide analog reverse transcriptase inhibitors (NRTIs) or as part of the fixed-dose combination (FDC) of DOR/lamivudine (3TC)/tenofovir disproxil fumarate (TDF) in participants ≥6 to \<12 years and weighing ≥14 to \<45 kg. * To evaluate the safety and tolerability of DOR when given with 2 NRTIs or as part of the FDC of DOR/3TC/TDF, in participants ≥6 to 12 years and weighing ≥14 to \<45 kg, through Week 24.

Conditions

  • Human Immunodeficiency Virus (HIV) Infection

Interventions

  • DoravirineDrug

    Administered orally

  • 2 NRTIsDrug

    Administered orally

  • DOR/3TC/TDFDrug

    Administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration-Time Curve (AUC) From 0 to 24 Hours Postdose (AUC0-24hr) of Doravirine (DOR) Following Once-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
  2. Maximum Concentration (Cmax) of DOR Following Once-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
  3. Concentration at 24 Hours (C24) of DOR Following Once-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
  4. Time to Maximum Concentration (Tmax) of DOR Following Once-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 24 hours postdose
  5. AUC From 0 to 12 Hours Postdose (AUC0-12hr) of DOR Following Twice-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
  6. Cmax of DOR Following Twice-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
  7. Concentration at 12 Hours (C12) of DOR Following Twice-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
  8. Tmax of DOR Following Twice-Daily Dosing in Plasma at Steady-StateTime frame: Intensive pharmacokinetic sampling: at designated timepoints up to 12 hours postdose
  9. Percentage of Participants With ≥1 Adverse Event (AE)Time frame: Up to 24 weeks
  10. Percentage of Participants With a Grade 3 or 4 AETime frame: Up to 24 weeks
  11. Percentage of Participants With Events of DeathTime frame: Up to 24 weeks
  12. Percentage of Participants Discontinuing From Study Intervention Due to an AETime frame: Up to 24 weeks
  13. Percentage of Participants Discontinuing From Study Intervention Due to a Drug-Related AETime frame: Up to 24 weeks

Locations

26 sites in 8 countries. Site status is shown where the registry gives one.

  • University of Colorado at Denver ( Site 0108)

    Aurora, Colorado · Completed

  • Emory Children's Center ( Site 0103)

    Atlanta, Georgia · Recruiting

  • Clinica Somer ( Site 1003)

    Rionegro, Antioquia, Colombia · Recruiting

  • Ciensalud Ips S A S ( Site 1001)

    Barranquilla, Atlántico, Colombia · Recruiting

  • CEIP - Centro de Estudios en Infectología Pediátrica ( Site 1002)

    Cali, Valle del Cauca Department, Colombia · Completed

  • Instituto Dermatológico y Cirugía de Piel "Dr. Huberto Bogaert Díaz" ( Site 1100)

    Santo Domingo, Dominican Republic · Recruiting

  • Clínica Médica Especializada en Pediatría e Infectología Pediátrica - Dr. Mario Melgar ( Site 1201)

    Guatemala City, Guatemala · Recruiting

  • Instituto Nacional de Pediatria ( Site 0701)

    Coyoacán, Mexico City, Mexico · Completed

  • Hospital Infantil de Mexico Federico Gomez ( Site 0702)

    Mexico City, Mexico City, Mexico · Active not recruiting

  • Unidad de Atencion Medica e Investigacion en Salud S.C. ( Site 0700)

    Mérida, Yucatán, Mexico · Completed

  • Kuzbasskiy Center for the Prevention and Control of AIDS ( Site 0506)

    Kemerovo, Kemerovo Oblast, Russia · Active not recruiting

  • Clinical Centre for Prevention and Control of AIDS ( Site 0504)

    Krasnodar, Krasnodarskiy Kray, Russia · Completed

  • Krasnoyarsk Regional Center for Prevention and Control of AIDS ( Site 0507)

    Krasnoyarsk, Krasnoyarsk Krai, Russia · Completed

  • Infectious Clinical Hospital #2 ( Site 0501)

    Moscow, Moscow, Russia · Completed

  • FGU Republican Clinical Infectious Hospital of Roszdrav ( Site 0500)

    Saint Petersburg, Sankt-Peterburg, Russia · Active not recruiting

  • FARMOVS PTY LTD ( Site 0601)

    Bloemfontein, Free State, South Africa · Completed

  • Perinatal HIV Research Unit ( Site 0602)

    Johannesburg, Gauteng, South Africa · Recruiting

  • Wits Reproductive Health and HIV Institute (WRHI) ( Site 0603)

    Johannesburg, Gauteng, South Africa · Recruiting

  • Empilweni Services and Research Unit ( Site 0604)

    Johannesburg, Gauteng, South Africa · Completed

  • King Edward Hospital ( Site 0600)

    Durban, KwaZulu-Natal, South Africa · Recruiting

  • Family Clinic Research With UBUNTU ( Site 0605)

    Cape Town, Western Cape, South Africa · Recruiting

  • Be Part Yoluntu Centre ( Site 0606)

    Paarl, Western Cape, South Africa · Recruiting

  • Tsitsikamma Clinical Research Initiative (TCRI) ( Site 0607)

    Plettenberg Bay, Western Cape, South Africa · Completed

  • Research Institute for Health Sciences ( Site 0902)

    Chiang Mai, Thailand · Recruiting

  • Faculty of Medicine - Khon Kaen University ( Site 0903)

    Khon Kaen, Thailand · Recruiting

  • Siriraj Hospital ( Site 0901)

    Bangkok, Bangkok, Thailand · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.